Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EQ NASDAQ:IVVD NASDAQ:LVTX NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$2.31+1.3%$2.77$0.37▼$3.54$146.06M1.77633,900 shs179,761 shsIVVDInvivyd$0.57+4.8%$0.89$0.48▼$3.07$167.63M0.673.58 million shs1.10 million shsLVTXLAVA Therapeutics$1.74$1.72$1.17▼$1.83$45.77M0.5187,834 shsN/AOKUROnKure Therapeutics$4.08+3.2%$4.27$1.91▼$5.38$165.20M0.27264,715 shs29,624 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium-1.72%-17.39%-25.97%+11.76%+471.43%IVVDInvivyd-8.48%-12.43%-42.46%-61.21%-32.67%LVTXLAVA Therapeutics0.00%0.00%0.00%0.00%+18.37%OKUROnKure Therapeutics0.00%-8.56%-12.22%-25.05%+74.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEQEquillium$2.31+1.3%$2.77$0.37▼$3.54$146.06M1.77633,900 shs179,761 shsIVVDInvivyd$0.57+4.8%$0.89$0.48▼$3.07$167.63M0.673.58 million shs1.10 million shsLVTXLAVA Therapeutics$1.74$1.72$1.17▼$1.83$45.77M0.5187,834 shsN/AOKUROnKure Therapeutics$4.08+3.2%$4.27$1.91▼$5.38$165.20M0.27264,715 shs29,624 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEQEquillium-1.72%-17.39%-25.97%+11.76%+471.43%IVVDInvivyd-8.48%-12.43%-42.46%-61.21%-32.67%LVTXLAVA Therapeutics0.00%0.00%0.00%0.00%+18.37%OKUROnKure Therapeutics0.00%-8.56%-12.22%-25.05%+74.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEQEquillium 2.82Moderate Buy$7.57227.77% UpsideIVVDInvivyd 2.33Hold$8.001,305.98% UpsideLVTXLAVA Therapeutics 1.67Reduce$1.37-21.26% DownsideOKUROnKure Therapeutics 2.00Hold$21.00415.34% UpsideCurrent Analyst Ratings BreakdownLatest LVTX, IVVD, EQ, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/24/2026IVVDInvivyd Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/21/2026EQEquillium Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/20/2026OKUROnKure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.007/13/2026EQEquillium Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight7/13/2026EQEquillium Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/7/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2026EQEquillium Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026IVVDInvivyd HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/9/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/1/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEQEquillium$41.10M3.55N/AN/A$0.47 per share4.91IVVDInvivyd$53.43M3.14N/AN/A$1.04 per share0.55LVTXLAVA Therapeutics$4.99M9.17N/AN/A$1.06 per share1.64OKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)IVVDInvivyd-$52.49M-$0.31N/AN/AN/A-138.90%-53.48%-41.56%8/13/2026 (Estimated)LVTXLAVA Therapeutics-$25.11M-$0.86N/AN/AN/AN/A-107.63%-35.06%N/AOKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)Latest LVTX, IVVD, EQ, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026EQEquillium-$0.05N/AN/AN/AN/AN/A8/13/2026Q2 2026IVVDInvivyd-$0.15N/AN/AN/A$14.40 millionN/A8/11/2026Q2 2026OKUROnKure Therapeutics-$0.58N/AN/AN/A$0.17 millionN/A5/14/2026Q1 2026IVVDInvivyd-$0.08-$0.13-$0.05-$0.13$18.04 million$13.74 million5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEQEquilliumN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEQEquilliumN/A18.6218.62IVVDInvivydN/A6.476.47LVTXLAVA TherapeuticsN/A12.2712.27OKUROnKure TherapeuticsN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEQEquillium27.05%IVVDInvivyd70.36%LVTXLAVA TherapeuticsN/AOKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipEQEquillium17.84%IVVDInvivyd12.25%LVTXLAVA Therapeutics9.50%OKUROnKure Therapeutics2.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEQEquillium4063.23 million51.95 millionNot OptionableIVVDInvivyd100294.61 million258.52 millionOptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableOKUROnKure TherapeuticsN/A40.40 million39.52 millionN/ALVTX, IVVD, EQ, and OKUR HeadlinesRecent News About These CompaniesADAR1 Capital Management LLC Acquires 1,420,783 Shares of OnKure Therapeutics, Inc. $OKURJuly 29 at 3:03 AM | marketbeat.comHC Wainwright Issues Positive Outlook for OKUR EarningsJuly 24, 2026 | americanbankingnews.comHC Wainwright Analysts Lift Earnings Estimates for OKURJuly 22, 2026 | marketbeat.comOnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets NearJuly 15, 2026 | marketbeat.comOnKure Therapeutics Stock Short Interest Report | NASDAQ:OKUR | BenzingaJuly 14, 2026 | benzinga.comOnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 211.1% in JuneJuly 13, 2026 | marketbeat.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.04%July 10, 2026 | aaii.comAOnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026July 2, 2026 | globenewswire.comOnKure Therapeutics, Inc. Class AJune 9, 2026 | edition.cnn.comOnKure Shareholders Approve Amended 2024 Equity Incentive PlanJune 4, 2026 | tipranks.comOnkure Therapeutics (OKUR) Stock Forecast & Price TargetMay 22, 2026 | investing.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.comOnKure Therapeutics war chest nears $200M following spring stock saleMay 6, 2026 | bizwest.comBOnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...March 27, 2026 | finance.yahoo.comOnKure to sell $150M in stock to fund drug developmentMarch 27, 2026 | bizwest.comBOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesMarch 27, 2026 | globenewswire.comOnKure reports nearly $60M cash on hand as drug trials continueMarch 19, 2026 | bizwest.comBOnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBroadcom's $30 Billion Apple Deal: This Chip Giant Is About More than Just AIBy Leo Miller | July 10, 2026Could Truth API Become Trump Media’s First Meaningful Revenue Driver?By Jeffrey Neal Johnson | July 22, 2026The Market Just Got Shaken—These 3 ETFs May Come Out StrongerBy Ryan Hasson | July 8, 2026This Dividend ETF Choice Could Shape Your Income Strategy Through 2026By Jessica Mitacek | July 12, 2026Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AIBy Jeffrey Neal Johnson | July 2, 2026LVTX, IVVD, EQ, and OKUR Company DescriptionsEquillium NASDAQ:EQ$2.31 +0.03 (+1.32%) As of 01:14 PM Eastern This is a fair market value price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Invivyd NASDAQ:IVVD$0.57 +0.03 (+4.79%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.LAVA Therapeutics NASDAQ:LVTXLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.OnKure Therapeutics NASDAQ:OKUR$4.08 +0.13 (+3.16%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
